New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis

被引：36

作者：

Prieto-Perez, R. ^{[1
]}

Solano-Lopez, G. ^{[2
]}

Cabaleiro, T. ^{[1
,3
]}

Roman, M. ^{[1
]}

Ochoa, D. ^{[1
]}

Talegon, M. ^{[1
]}

Baniandres, O. ^{[4
]}

Lopez-Estebaranz, J. L. ^{[5
]}

de la Cueva, P. ^{[6
]}

Dauden, E. ^{[2
]}

Abad-Santos, F. ^{[1
,3
]}

机构：

[1] Univ Autonoma Madrid, Inst Teofilo Hernando, Hosp Univ la Princesa, Clin Pharmacol Serv,Inst Invest Sanitaria la Prin, Madrid, Spain

[2] Hosp Univ la Princesa, Inst Invest Sanitaria la Princesa IP, Dermatol Serv, Madrid, Spain

[3] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

[4] Hosp Univ Gregorio Maranon, Dermatol Serv, Madrid, Spain

[5] Hosp Univ Fdn Alcorcon, Dermatol Serv, Madrid, Spain

[6] Hosp Univ Infanta Leonor, Dermatol Serv, Madrid, Spain

来源：

PHARMACOGENOMICS JOURNAL | 2018年 / 18卷 / 01期

关键词：

GENOME-WIDE ASSOCIATION; RHEUMATOID-ARTHRITIS; GENE POLYMORPHISMS; RECEPTOR GENE; CANDIDATE GENES; ALPHA BLOCKERS; PSORS4; LOCUS; RISK GENES; SUSCEPTIBILITY; POPULATION;

D O I：

10.1038/tpj.2016.64

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Anti-tumor necrosis factor (anti-TNF) drugs are effective against psoriasis, although 20-30% of patients are nonresponders. Few pharmacogenomic studies have been performed to predict the response to anti-TNF drugs in psoriasis. We studied 173 polymorphisms to establish an association with the response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis (N = 144). We evaluated the response using PASI75 at 3, 6 and 12 months. The results of the multivariate analysis showed an association between polymorphisms in PGLYR4, ZNF816A, CTNNA2, IL12B, MAP3K1 and HLA-C genes and the response at 3 months. Besides, the results for polymorphisms in IL12B and MAP3K1 were replicated at 6 months. We also obtained significant results for IL12B polymorphism at 1 year. Moreover, polymorphisms in FCGR2A, HTR2A and CDKAL1 were significant at 6 months. This is the first study to show an association with these polymorphisms. However, these biomarkers should be validated in large-scale studies before implementation in clinical practice.

引用

页码：70 / 75

页数：6

共 45 条

[1] The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients
Batalla, Ana
Coto, Eliecer
Gonzalez-Fernandez, Daniel
Gonzalez-Lara, Leire
Gomez, Juan
Santos-Juanes, Jorge
Queiro, Ruben
Coto-Segura, Pablo
[J]. PHARMACOGENETICS AND GENOMICS, 2015, 25 (06) : 313 - 316
[2] Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients
Bowes, John D.
Potter, Catherine
Gibbons, Laura J.
Hyrich, Kimme
Plant, Darren
Morgan, Ann W.
Wilson, Anthony G.
Isaacs, John D.
Worthington, Jane
Barton, Anne
[J]. PHARMACOGENETICS AND GENOMICS, 2009, 19 (04) : 319 - 323
[3] Influence of variants of Fcγ receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to antitumour necrosis factor α therapy in rheumatoid arthritis
Canete, J. D.
Suarez, B.
Hernandez, M. V.
Sanmarti, R.
Rego, I.
Celis, R.
Moll, C.
Pinto, J. A.
Blanco, F. J.
Lozano, F.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (10) : 1547 - 1552
[4] A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes
Cargill, Michele
Schrodi, Steven J.
Chang, Monica
Garcia, Veronica E.
Brandon, Rhonda
Callis, Kristina P.
Matsunami, Nori
Ardlie, Kristin G.
Civello, Daniel
Catanese, Joseph J.
Leong, Diane U.
Panko, Jackie M.
McAllister, Linda B.
Hansen, Christopher B.
Papenfuss, Jason
Prescott, Stephen M.
White, Thomas J.
Leppert, Mark F.
Krueger, Gerald G.
Begovich, Ann B.
[J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2007, 80 (02) : 273 - 290
[5] -174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-α blockers
Di Renzo, Laura
Bianchi, Alessia
Saraceno, Rosita
Calabrese, Vittorio
Cornelius, Caroline
Iacopino, Leonardo
Chimenti, Sergio
De Lorenzo, Antonino
[J]. PHARMACOGENETICS AND GENOMICS, 2012, 22 (02) : 134 - 142
[6] Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis
Elder, J. T.
[J]. GENES AND IMMUNITY, 2009, 10 (03) : 201 - 209
[7] Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2
Ellinghaus, Eva
Ellinghaus, David
Stuart, Philip E.
Nair, Rajan P.
Debrus, Sophie
Raelson, John V.
Belouchi, Majid
Fournier, Helene
Reinhard, Claudia
Ding, Jun
Li, Yun
Tejasvi, Trilokraj
Gudjonsson, Johann
Stoll, Stefan W.
Voorhees, John J.
Lambert, Sylviane
Weidinger, Stephan
Eberlein, Bernadette
Kunz, Manfred
Rahman, Proton
Gladman, Dafna D.
Gieger, Christian
Wichmann, H. Erich
Karlsen, Tom H.
Mayr, Gabriele
Albrecht, Mario
Kabelitz, Dieter
Mrowietz, Ulrich
Abecasis, Goncalo R.
Elder, James T.
Schreiber, Stefan
Weichenthal, Michael
Franke, Andre
[J]. NATURE GENETICS, 2010, 42 (11) : 991 - U113
[8] Multiple Loci within the Major Histocompatibility Complex Confer Risk of Psoriasis
Feng, Bing-Jian
Sun, Liang-Dan
Soltani-Arabshahi, Razieh
Bowcock, Anne M.
Nair, Rajan P.
Stuart, Philip
Elder, James T.
Schrodi, Steven J.
Begovich, Ann B.
Abecasis, Goncalo R.
Zhang, Xue-Jun
Callis-Duffin, Kristina P.
Krueger, Gerald G.
Goldgar, David E.
[J]. PLOS GENETICS, 2009, 5 (08):
[9] Gaber MAE, 2015, INDIAN DERMATOL ONL, V6, P13, DOI [10.4103/2229-5178.148923, DOI 10.4103/2229-5178.148923]
[10] The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study
Gallo, E.
Cabaleiro, T.
Roman, M.
Solano-Lopez, G.
Abad-Santos, F.
Garcia-Diez, A.
Dauden, E.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 (04) : 819 - 829

← 1 2 3 4 5 →